These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 17045635

  • 1. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
    Spannuth WA, Leath CA, Huh WK, Barnes MN, Davidson SA, Kilgore LC, Partridge EE, Austin JM, Alvarez RD.
    Gynecol Oncol; 2007 Mar; 104(3):591-5. PubMed ID: 17045635
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T, Inbar M, Menczer J, Grisaru D, Glezerman M, Safra T.
    Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B, Hansen HH, Høgdall C, Engelholm SA.
    Cancer; 2002 Oct 15; 95(8):1656-62. PubMed ID: 12365013
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
    Safra T, Menczer J, Bernstein R, Shpigel S, Inbar MJ, Grisaru D, Golan A, Levy T.
    Gynecol Oncol; 2007 Apr 15; 105(1):205-10. PubMed ID: 17239430
    [Abstract] [Full Text] [Related]

  • 5. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC.
    Gynecol Oncol; 2008 Jan 15; 108(1):53-7. PubMed ID: 17904208
    [Abstract] [Full Text] [Related]

  • 6. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG, Gordon NH, Fusco N, Fluellen L, Rodriguez M, Ingalls ST, Hoppel CL.
    Gynecol Oncol; 2000 Aug 15; 78(2):228-34. PubMed ID: 10926808
    [Abstract] [Full Text] [Related]

  • 7. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
    O'Malley DM, Azodi M, Makkenchery A, Tangir J, McAlpine J, Kelly M, Schwartz P, Rutherford T.
    Gynecol Oncol; 2005 Aug 15; 98(2):242-8. PubMed ID: 15992916
    [Abstract] [Full Text] [Related]

  • 8. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ.
    Gynecol Oncol; 1997 Sep 15; 66(3):480-6. PubMed ID: 9299264
    [Abstract] [Full Text] [Related]

  • 9. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG.
    Gynecol Oncol; 2008 Dec 15; 111(3):467-73. PubMed ID: 18834619
    [Abstract] [Full Text] [Related]

  • 10. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
    Miller DS, Blessing JA, Lentz SS, McMeekin DS.
    Cancer; 2003 Oct 15; 98(8):1664-9. PubMed ID: 14534883
    [Abstract] [Full Text] [Related]

  • 11. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
    Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG.
    Gynecol Oncol; 2006 Nov 15; 103(2):637-41. PubMed ID: 16781766
    [Abstract] [Full Text] [Related]

  • 12. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
    Kang H, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG.
    Gynecol Oncol; 2009 Aug 15; 114(2):210-4. PubMed ID: 19446320
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J.
    Semin Oncol; 1997 Feb 15; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [Abstract] [Full Text] [Related]

  • 14. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
    Le T, Hopkins L, Baines KA, Rambout L, Al Hayki M, Kee Fung MF.
    Gynecol Oncol; 2006 Jul 15; 102(1):49-53. PubMed ID: 16375951
    [Abstract] [Full Text] [Related]

  • 15. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma.
    Elkas JC, Winter WE, Chernofsky MR, Sunde J, Bidus MA, Bernstein S, Rose GS.
    Gynecol Oncol; 2007 Feb 15; 104(2):422-7. PubMed ID: 16996118
    [Abstract] [Full Text] [Related]

  • 16. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    Gynecol Oncol; 2000 Oct 15; 79(1):116-9. PubMed ID: 11006042
    [Abstract] [Full Text] [Related]

  • 17. Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases.
    Phippen NT, Leath CA.
    J Reprod Med; 2009 Sep 15; 54(9):583-6. PubMed ID: 19947038
    [Abstract] [Full Text] [Related]

  • 18. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
    Markman M, Blessing JA, Alvarez RD, Hanjani P, Waggoner S, Hall K.
    Gynecol Oncol; 2000 Apr 15; 77(1):112-5. PubMed ID: 10739699
    [Abstract] [Full Text] [Related]

  • 19. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
    Stathopoulos GP, Malamos NA, Aravantinos G, Rigatos S, Christodoulou Ch, Stathopoulos J, Skarlos D.
    Cancer Chemother Pharmacol; 2007 Jun 15; 60(1):123-8. PubMed ID: 17111119
    [Abstract] [Full Text] [Related]

  • 20. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
    Ramasubbaiah R, Perkins SM, Schilder J, Whalen C, Johnson CS, Callahan M, Jones T, Sutton G, Matei D.
    Gynecol Oncol; 2011 Dec 15; 123(3):499-504. PubMed ID: 21955480
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.